DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
A phase 3 trial of Trastuzumab emtansine in her2-positive breast cancer, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.
Overview
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer is a phase 3 interventional study registered as NCT06313086 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 442 participants planned, started 2024-03-13 and due to reach its primary completion in 2025-12. Interventions recorded: DP303c, trastuzumab emtansine. Conditions listed: HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Setting
A Multicentre, Randomized, Open-label, Controlled Phase Ш Clinical Study to Evaluate the Efficacy and Safety of DP303c Versus Trastuzumab Emtansine in Patients With HER2-positive Advanced Breast Cancer
Phase
Phase 3
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Registry
Enrolled
442
Similar pages
not linked directly; found by shared links- TrialHER2CLIMB-02
- TrialJSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
- TrialA Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
- TrialEfficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer
Shares CSPC Pharmaceutical Group, HER2-positive breast cancer.
- TrialA Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
- TrialA Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
- TrialA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- PersonEleftherios P. Mamounas